Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

Blood

Volumn 103, Issue 9, 2004, Pages 3503-3510

  Nefedova, Yulia ^a   Cheng, Pingyan ^a   Alsina, Melissa ^a   Dalton, William S ^a   Gabrilovich, Dmitry I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; MITOXANTRONE; NOTCH1 RECEPTOR;

ARTICLE; BONE MARROW CELL; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; UPREGULATION;

EID: 1942425110     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2340     Document Type: Article

References (49)

1. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175-1182.
2. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
3. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAMDR). Oncogene. 2000;19:4319-4327.
4. Dalton W. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003;29:11-19.
5. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opinion Oncol. 2000;12:557-563.
6. Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001;1:69-78.
7. Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood. 1999;93:2431-2448.
8. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999;181:393-409.
9. Ohishi K, Varnum-Finney B, Bernstein ID. The notch pathway: modulation of cell fate decisions in hematopoiesis. Int J Hematol. 2002;75:449-459.
10. Kao H, Ordentlich P, Koyano-Nakagawa N, et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 1998;12:2269-2277.
11. Bertrand FE, Eckfeldt CE, Lysholm AS, LeBien TW. Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells. Leukemia. 2000;14:2095-2102.
12. Walker L, Carlson A, Tan-Pertel HT, Weinmaster G, Gasson J. The Notch receptor and its ligands are selectively expressed during hematopoietic development in the mouse. Stem Cells. 2001;19:543-552.
13. Li L, Milner LA, Deng Y, et al. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity. 1998;8:43-55.
14. Felli MP, Maroder M, Mitsiadis TA, et al. Expression pattern of notch1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components: distinct ligand-receptor interactions in intrathymic T cell development. Int Immunol. 1999;11:1017-1025.
15. Rangarajan A, Syal R, Selvarajah S, Chakrabarti O, Sarin A, Krishna S. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology. 2001;286:23-30.
16. Ellisen L, Bird J, West D, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661.
17. Zagouras P, Stifani S, Blaumueller C, Carcangiu M, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A. 1995;92:6414-6418.
18. Rae F, Stephenson S, Nicol D, Clements J. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer. 2000;88:726-732.
19. Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001;42:467-472.
20. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398-3403.
21. Jeffries S, Capobianco AJ. Neoplastic transformation by Notch requires nuclear localization. Mol Cell Biol. 2000;20:3928-3941.
22. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002;8:979-986.
23. Ronchini C, Capobianco AJ. Induction of cyclin d1 transcription and cdk2 activity by Notch (IC): implication for cell cycle distribution in transformation by Notch (IC). Mol Cell Biol. 2001;21:5925-5934.
24. Han W, Ye Q, Moore MA. A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells. Blood. 2000;95:1616-1625.
25. Cheng P, Zlobin A, Volgina V, et al. Notch-1 regulates NF-kappa B activity in hematopoietic progenitor cells. J Immunol. 2001;167:4458-4467.
26. Carlesso N, Aster JC, Sklar J, Scadden DT. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 1999;93:838-848.
27. Drexler HG, McLeod RAF, Dirks W. Cross-contamination: HS-Sultan is not a myeloma but a Burkitt lymphoma cell line. Blood. 2001;98:3495-3496.
28. Pellat-Deceunynk C, Amiot M, Bataille R, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood. 1995;86:4001-4002.
29. Varnum-Finney B, Purton LE, Yu M, et al. The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood. 1998;91:4084-4091.
30. Osbom L, Kunkel S, Nabel GJ. Tumor necrosis factor and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A. 1989;86:2336-2340.
31. Cheng P, Zlobin A, Volgina V, et al. Notch-1 regulates NF-kappaB activity in hematopoietic progenitor cells. J Immunol. 2001;167:4458-4467.
32. Bharti A, Aggarwal B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002;64:883-888.
33. Mitsiades N, Mitsiades C, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
34. Nickoloff BJ, Qin J-Z, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of Notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ. 2002;9:842-855.
35. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol. 1998;18:2077-2088.
36. Steinman RA. Cell cycle regulators and hematopoiesis. Oncogene. 2002;21:3403-3413.
37. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia. 2001;15:264-271.
38. Garrido GM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448-457.
39. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000;96:1926-1932.
40. Osbome B, Miele L. Notch and the immune system. Immunity. 1999;11:653-663.
41. Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20:3427-3436.
42. Sriuranpong V, Borges M, Ravi R, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200-3205.
43. Kabos P, Kabosova A, Neuman T. Blocking of HES1 expression initiates GABAergic differentiation and induces the expression of p21 in human neural stem cells. J Biol Chem. 2002;277:8763-8766.
44. Carlesso N, Aster J, Sklar J, Scadden D. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood. 1999;93:838-848.
45. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood. 2000;96:3175-3180.
46. Rowley M, Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response, Oncogene. 2002;21:8769-8775.
47. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003;17:451-457.
48. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770-776.
49. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398-3403.